---
title: "Tremfya (guselkumab) in plaque psoriasis: Access and coverage questions"
description: "Access and coverage questions on Tremfya (guselkumab) in plaque psoriasis, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Prior authorization. Questions: What is needed for Tremfya prior authorization? 1 question quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/tremfya--plaque-psoriasis/access-and-coverage"
published: "2026-11-13T03:43:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Tremfya (guselkumab) in plaque psoriasis: Access and coverage questions

Manufacturer: Janssen Biotech, Inc.  
Prescribing information: [Tremfya](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/TREMFYA-pi.pdf)

Access and coverage questions that apply to every indication of Tremfya are on [Tremfya (guselkumab), all indications: Access and coverage](https://www.evicenter.com/medical-information/tremfya/access-and-coverage).

## Prior authorization

<a id="tremfya-prior-authorization"></a>

### What is needed for Tremfya prior authorization?

> “Each health plan may have its own unique prior authorization (PA) form with varying requirements. It is important to gather 
> necessary information during the patient’s first appointment to ensure an effective process with minimal delays.”

Source: [TREMFYA: Tremfya_Prior_Authorization_Checklist.pdf, page 1, captured 2026-11-13](https://www.tremfyahcp.com/plaque-psoriasis/files/Tremfya_Prior_Authorization_Checklist.pdf#page=1)

> “4 Essentials for Approval
> 1
> Diagnosis must match FDA indication for TREMFYA<sup>®</sup>
> •  Diagnosis must be moderate to severe plaque psoriasis 
> and/or active psoriatic arthritis
> •  For moderate to severe plaque psoriasis, the patient must 
> be a candidate for phototherapy or systemic therapy even 
> if not on treatment”

Source: [TREMFYA: Tremfya_Prior_Authorization_Checklist.pdf, page 1, captured 2026-11-13](https://www.tremfyahcp.com/plaque-psoriasis/files/Tremfya_Prior_Authorization_Checklist.pdf#page=1)

> “Tuberculosis (TB) test results must be included”

Source: [TREMFYA: Tremfya_Prior_Authorization_Checklist.pdf, page 1, captured 2026-11-13](https://www.tremfyahcp.com/plaque-psoriasis/files/Tremfya_Prior_Authorization_Checklist.pdf#page=1)

> “Notes of previously used medicines, response 
> to therapy (patient has tried and failed topicals, 
> phototherapy, and DMARDs), and other medical 
> record documentation must be included”

Source: [TREMFYA: Tremfya_Prior_Authorization_Checklist.pdf, page 1, captured 2026-11-13](https://www.tremfyahcp.com/plaque-psoriasis/files/Tremfya_Prior_Authorization_Checklist.pdf#page=1)

> “Always indicate the starter dose (100 mg/mL SC at 
> Week 0 and Week 4) and maintenance therapy dosing 
> (100 mg/mL every 8 weeks after)”

Source: [TREMFYA: Tremfya_Prior_Authorization_Checklist.pdf, page 1, captured 2026-11-13](https://www.tremfyahcp.com/plaque-psoriasis/files/Tremfya_Prior_Authorization_Checklist.pdf#page=1)

> “Supporting Clinical Information for Moderate to 
> Severe Plaque Psoriasis
> • Psoriasis Area and Severity Index (PASI)/Investigator's 
>   Global  Assessment (IGA) Score
> • % Body Surface Area Coverage
> • Disease Severity”

Source: [TREMFYA: Tremfya_Prior_Authorization_Checklist.pdf, page 1, captured 2026-11-13](https://www.tremfyahcp.com/plaque-psoriasis/files/Tremfya_Prior_Authorization_Checklist.pdf#page=1)

Note: The checklist covers both plaque psoriasis and psoriatic arthritis.

## Related pages
- [Medical information: Tremfya (guselkumab): Plaque psoriasis](https://www.evicenter.com/medical-information/tremfya--plaque-psoriasis)
- [Indication](https://www.evicenter.com/medical-information/tremfya--plaque-psoriasis/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/tremfya--plaque-psoriasis/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/tremfya--plaque-psoriasis/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/tremfya--plaque-psoriasis/safety)
- [Specific populations](https://www.evicenter.com/medical-information/tremfya--plaque-psoriasis/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/tremfya--plaque-psoriasis/dosing-and-administration)
- [Guidelines](https://www.evicenter.com/medical-information/tremfya--plaque-psoriasis/guidelines)
